The following is a selected list of our commercial and licensing partners. Will you join this network dedicated to advancing novel and effective vaccines?
BeijingZhifei Lvzhu Biopharmaceutical Co., Ltd is a leading company in the area of human vaccines and related products and technologies in the People’s Republic of China. Zhifei Lvzhu received an exclusive license for the Chinese territory for our Avacc® 3 in 2022, an OMV-based whooping cough vaccine. Both parties collaborate to tailor the Avacc 3® concept vaccine, including upscaling, toxicology and clinical trials to commercialize the vaccine for the Chinese market.
Chongqing Zhifei Biological Products Co.,Ltd.
Dr. Yao Lei, Head R&D, Zhifei
“Worldwide resurgence of whooping cough calls for improved, next-generation pertussis vaccines that induce broad and long-lasting immunity. A pertussis vaccine based on outer membrane vesicles is a promising candidate. We have successfully in-licensed the pertussis OMV technology from Intravacc recently. Our efforts are focused on advancing this innovative vaccine technology through the clinical pipeline, with the aim of combatting the resurgence of whooping cough using Pertussis Vaccine based on OMV technology”.
Picture:The team of Dr. Yao Lei (in the middle) and the team of Intravacc during the technology transfer at Intravacc in Bilthoven, The Netherlands, in June 2023.
Intravacc collaborates with the German Center of Neurodegenerative Diseases (DZNE) in an EU funded project called GA-VAX. The goal is to develop a preventive as well as therapeutic vaccine for a subtype of ALS that is caused by an inherited genetic disorder (C9orf72 ALS). Current results show benefit in prevention and treatment in the mouse model. It is planned to do a clinical phase I study starting 2025.
Serum Institute of India Pvt. Ltd. is now the world's largest vaccine manufacturer by number of doses produced and sold globally. It is estimated that about 65% of the children in the world receive at least one vaccine manufactured by Serum Institute.
Therapyx, based in Buffalo, NY, is a privately held development-stage biotechnology company committed to innovating our industry and changing the future of pharmaceuticals by engaging in the discovery and development of microparticulate immune therapeutics to treat infectious disease, immune-mediated inflammatory disorders, and cancer. Intravacc collaborates with Therapyx to further develop and optimize a prophylactic vaccine against gonorrhea, Avacc® 11. Avacc 11 is a vaccine consisting of Outer Membrane Vesicles from the bacterium Neisseria gonorrhoeae, developed with Intravacc's OMV-Vacc platform and microsphere-encapsulated interleukin-12 (IL-12). Thus, this vaccine consists of a combination of adjuvant and antigen and is specifically designed for mucosal immunization.
Liaoning Chengda Biotechnology CO., Ltd. (CDBIO) holds a prominent position in the field of human vaccines and associated products and technologies within the People’s Republic of China. Currently, CDBIO is engaged in a collaborative effort with Intravacc to advance the development of a vaccine targeting meningococcal type B disease, utilizing Intravacc’s proprietary Nonamen® vaccine technology. Both organizations are actively working together to customize the Nonamen concept to align with the specific needs of the Chinese market.
Established in 2004 and situated in Changchun, Changchun BCHT Biotechnology Co. (BCHT) is a biopharmaceutical enterprise specializing in research, development, production, and marketing of vaccines, biologics, and peptide drugs. Intravacc and BCHT collaborate on the ongoing development of a Haemophilus influenzae Type B (HiB) conjugate vaccine within the People’s Republic of China. Through this partnership, BCHT has gained access to Intravacc’s unique Hib conjugate technology for the further development, production, and distribution of the vaccine. This vaccine comprises Hib polysaccharide (poly-ribosylribitol phosphate, PRP) coupled with tetanus toxoid, proving highly effective in preventing the disease. Intravacc's Hib vaccine technology has already been employed to vaccinate hundreds of millions of children and holds WHO prequalification.
Sinovac is a China-based Biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines for infectious disease with significant unmet medical need. Intravacc and Sinovac are collaborating in the eradication of polio through the technology transfer of sIPV vaccine technology. Sinovac received market authorization for its sIPV vaccine in July 2021.
Established in 1947, LG Chem has grown to become Korea’s leading chemical company. Intravacc successfully transferred its sIPV technology to LG Chem and supported its implementation at the LG Chem site. Clinical studies for the vaccine have been completed and market licensure and WHO-prequalification have been obtained. Commercial manufacturing of the vaccines is ongoing as part of the Polio Eradication Campaign.
Beijing Minhai is primarily engaged in the development, production, and sale of biological vaccine products. Intravacc and Minhai are currently collaborating on implementing the sIPV (Sabin Inactivated Poliovirus Vaccine) technology at Minhai's facilities. This sIPV vaccine technology developed by Minhai has progressed through Phase II clinical studies in China.
You can send us an email:
info@intravacc.nl
Reach out to Business Development:
BD@intravacc.nl
Or pick up the phone:
+31 30 792 03 00
You can also just fill out the contact form on the right.
We look forward to hearing from you!
